News
2d
MedPage Today on MSNNovel IL-7 Receptor Antagonist Shows Promise in Ulcerative ColitisLusvertikimab selectively inhibits IL-7 but not the thymic stromal lymphopoietin (TSLP) axis, Bourreille told attendees. A ...
Proctitis causes rectal discomfort and bleeding. Learn what triggers it, how it's diagnosed, and which treatments actually ...
11d
Everyday Health on MSNHow Does Smoking Affect Ulcerative Colitis?Research shows that smoking may have beneficial effects on symptoms of ulcerative colitis. But the risks of starting this ...
Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...
If you have ulcerative colitis (UC), you know that the physical symptoms—which include things like abdominal and rectal ...
Discover a study that has revealed a new potential mechanism of understanding inflammation in ulcerative colitis.
Hunter Renfrow is mounting an NFL comeback after spending the 2024 season out of the league battling ulcerative colitis. Here ...
DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...
Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...
Talk to your doctor about whether you meet the criteria. What is the main cause of ulcerative colitis? The exact cause of ulcerative colitis is unknown, but it is believed to involve a combination ...
Hunter Renfrow is back in the NFL after taking last season off, and now we have a better understanding of what happened.
12d
Pharmaceutical Technology on MSNJ&J’s Tremfya gains EC marketing authorisation for ulcerative colitisThe EC has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya to treat adults with ulcerative colitis (UC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results